{{Chembox
| ImageFile = Zabofloxacin.svg
| ImageSize = 200px
| IUPACName = 1-Cyclopropyl-6-fluoro-7-[(8''E'')-8-(methoxyimino)-2,6-diazaspiro[3.4]oct-6-yl]-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
| OtherNames = DW-224a
|Section1={{Chembox Identifiers
| CASNo = 219680-11-2
| PubChem = 9952872
| ChemSpiderID = 8128482
| SMILES = Fc1c(nc2c(c1)C(=O)C(\C(=O)O)=C/N2C3CC3)N5C\C(=N\OC)C4(CNC4)C5
| InChI = 1/C19H20FN5O4/c1-29-23-14-6-24(9-19(14)7-21-8-19)17-13(20)4-11-15(26)12(18(27)28)5-25(10-2-3-10)16(11)22-17/h4-5,10,21H,2-3,6-9H2,1H3,(H,27,28)/b23-14-
| InChIKey = ZNPOCLHDJCAZAH-UCQKPKSFBL
| StdInChI = 1S/C19H20FN5O4/c1-29-23-14-6-24(9-19(14)7-21-8-19)17-13(20)4-11-15(26)12(18(27)28)5-25(10-2-3-10)16(11)22-17/h4-5,10,21H,2-3,6-9H2,1H3,(H,27,28)/b23-14-
| StdInChIKey = ZNPOCLHDJCAZAH-UCQKPKSFSA-N
  }}
|Section2={{Chembox Properties
| Formula = C<sub>19</sub>H<sub>20</sub>FN<sub>5</sub>O<sub>4</sub>
| MolarMass = 401.392
| Appearance = 
| Density = 
| MeltingPt = 
| BoilingPt = 
| Solubility =
  }}
|Section3={{Chembox Hazards
| MainHazards = 
| FlashPt = 
| AutoignitionPt =
  }}
}}

'''Zabofloxacin''' is an investigational [[fluoroquinolone antibiotic]] for multidrug-resistant infections due to [[Gram-positive bacteria]].<ref>{{cite journal | journal = Current Medical Research and Opinion | title = Comparison of pharmacokinetics between new quinolone antibiotics: the zabofloxacin hydrochloride capsule and the zabofloxacin aspartate tablet | date = October 2013 | volume = 29 | issue = 10  | pages = 1349–1355 | doi = 10.1185/03007995.2013.825591 |author1=HyeKyung Han |author2=Sung Eun Kim |author3=Kwang-Hee Shin |author4=Cheolhee Lim |author5=Kyoung Soo Lim |author6=Kyung-Sang Yu |author7=Joo-Youn Cho }}</ref><ref>{{cite journal | journal = Journal of Liquid Chromatography & Related Technologies | volume = 37 | issue = 3 | year = 2014 | title = Quantification Of Zabofloxacin In Rat Plasma Using Hplc-Uv Detector And Its Application To A Pharmacokinetic Study | doi = 10.1080/10826076.2012.745137 |author1=Jong-Hwa Lee |author2=Jung-Heun Ha |author3=Dae-Hun Park |author4=Dong-Rack Choi |author5=Gye-Won Lee |author6=Sung-Hoon Ahn |author7=Choong-Yong Kim  |last-author-amp=yes | pages = 311–320}}</ref><ref>{{cite journal | journal = Drug Chem Toxicol | date = Nov 2004 | volume = 27 | issue = 4 | pages = 295–307 | title = Safety pharmacology of DW-224a, a novel fluoroquinolone antibiotic agent |vauthors=Kim EJ, Shin WH, Kim KS, Han SS | pmid= 15573468 | doi=10.1081/DCT-200039708}}</ref>  It also has activity against ''[[Neisseria gonorrhoeae]]'' including strains that are resistant to other quinolone antibiotics.<ref>{{cite journal |vauthors=Jones RN, Biedenbach DJ, Ambrose PG, Wikler MA | title = Zabofloxacin (DW-224a) activity against Neisseria gonorrhoeae including quinolone-resistant strains | pmid= 18620833 | journal = Diagn Microbiol Infect Dis | year = 2008 | volume = 62 | issue = 1 | pages = 110–112 | doi = 10.1016/j.diagmicrobio.2008.05.010}}</ref>

Zabofloxacin was [[drug discovery|discovered]] by Dong Wha Pharmaceuticals and licensed to Pacific Beach BioSciences for [[drug development|development]].<ref>{{cite news | url = http://globenewswire.com/news-release/2007/08/10/364043/124686/en/Pacific-Beach-BioSciences-and-Dong-Wha-Pharmaceuticals-Sign-Exclusive-License-Agreement-to-Develop-and-Commercialize-Zabofloxacin-PB-101-DW-224a.html | title = Pacific Beach BioSciences and Dong Wha Pharmaceuticals Sign Exclusive License Agreement to Develop and Commercialize Zabofloxacin (PB-101, DW-224a) | publisher = GlobeNewswire | date = August 10, 2007}}</ref>

==References==
{{reflist}}

==External links==
* [http://www.tklresearch.com/Collateral/Documents/Common/Zabo%20Phase%20II-ICAAC(2012).pdf A Phase 2, Multi-dose, Double-Blind, Randomized, Multicenter, Safety and Efficacy Study of Zabofloxacin vs Moxifloxacin in the Treatment of Mild to Moderate Community-Acquired Pneumonia]

[[Category:Fluoroquinolone antibiotics]]